📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
JSLL Dehradun Hospital Receives NABH Accreditation Valid Until January 2029
Jeena Sikho Lifecare Limited (JSLL) has successfully secured the National Accreditation Board for Hospitals & Healthcare Providers (NABH) certification for its Dehradun facility. This accreditation specifically covers Panchakarma services at the Jakhan, Dehradun location and is valid until January 05, 2029. While this does not represent a physical expansion or capacity increase, it validates the company's adherence to high-quality healthcare standards and patient safety. Such certifications are crucial for building brand trust and potentially qualifying for government and insurance empanelments in the future.
Key Highlights
Awarded NABH accreditation for Dehradun Hospital (Jakhan) specifically for Panchakarma services.
The certification (No. AH-2026-0429) is valid for approximately three years until January 05, 2029.
Signifies adherence to nationally recognized standards for quality healthcare delivery and patient safety.
The accreditation occurred in the ordinary course of business and does not involve immediate capacity enhancement.
💼 Action for Investors
This is a positive development for long-term brand equity and service quality assurance. Investors should monitor if this accreditation leads to higher patient footfall or new insurance tie-ups for the Dehradun facility.
Jeena Sikho Lifecare Approves Q3 FY26 Unaudited Financial Results
Jeena Sikho Lifecare Limited (JSLL) has officially approved its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The board meeting was held on February 7, 2026, and concluded with the submission of the limited review report by statutory auditors. This announcement confirms the company's adherence to SEBI Listing Regulations 30 and 33. Investors should now focus on the detailed financial tables to assess the company's performance in the wellness and lifecare sector.
Key Highlights
Board approved unaudited standalone and consolidated results for the quarter ended December 31, 2025.
Statutory Auditors issued a Limited Review Report for the nine-month period ending December 2025.
The board meeting was conducted efficiently, starting at 04:05 P.M. and concluding at 04:35 P.M.
Compliance maintained under Regulation 30 and 33 of SEBI (LODR) Regulations, 2015.
💼 Action for Investors
Investors should analyze the detailed financial statements for revenue growth and EBITDA margins once the full report is accessed. Monitor the stock for any price volatility following the earnings release.
JSLL Q3 FY26 Results: Revenue Up 92% YoY, PAT Surges 405% to ₹66.73 Crore
Jeena Sikho Lifecare Limited (JSLL) delivered exceptional Q3 FY26 performance, with revenue growing 92% YoY to ₹221.66 crore. Profitability saw a massive boost as PAT surged 405% YoY to ₹66.73 crore, supported by EBITDA margins expanding from 26% to 45%. The growth was driven by a 247% YoY increase in OPD patient volumes and an 84% rise in IPD volumes. The company is aggressively expanding with 475+ beds in the pipeline, bringing total capacity towards 2,800 beds.
Key Highlights
Revenue from operations increased 92% YoY to ₹221.66 crore in Q3 FY26.
PAT skyrocketed 405% YoY to ₹66.73 crore with PAT margins reaching 30%.
EBITDA margins expanded significantly to 45% compared to 26% in Q3 FY25.
OPD, COD, and Video-Call patient volumes grew 247% YoY to 4.34 lakhs.
Current operational capacity is 2,290 beds with 475+ additional beds under development.
💼 Action for Investors
Investors should view the massive margin expansion and volume growth as a sign of high operational leverage and scalability. The company's transition to the mainboard and its aggressive bed expansion pipeline make it a strong growth candidate in the Ayurvedic healthcare sector.
Jeena Sikho Lifecare Approves Q3 FY26 Unaudited Standalone and Consolidated Financial Results
Jeena Sikho Lifecare Limited (JSLL) has announced its financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved both standalone and consolidated unaudited results during their meeting on February 7, 2026. The filing includes the Limited Review Report from statutory auditors, ensuring regulatory compliance under SEBI guidelines. Investors should now focus on the detailed financial statements to evaluate the company's growth and margin performance in the healthcare sector.
Key Highlights
Board approved unaudited standalone and consolidated financial results for the quarter ended Dec 31, 2025.
Statutory auditors provided a Limited Review Report for the nine-month period ending December 2025.
The board meeting was conducted and concluded within a 30-minute window (04:05 P.M. to 04:35 P.M.).
Compliance maintained as per Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
💼 Action for Investors
Investors should scrutinize the detailed profit and loss statements and balance sheet figures to assess the company's operational efficiency. Compare the Q3 results with previous quarters to identify any seasonal trends or growth momentum in the lifecare business.
Jeena Sikho Lifecare Board Approves Unaudited Q3 and Nine-Month FY26 Financial Results
Jeena Sikho Lifecare Limited (JSLL) held a board meeting on February 7, 2026, to approve its financial performance for the period ending December 31, 2025. The board cleared both standalone and consolidated unaudited results, supported by a limited review report from statutory auditors. This meeting marks the official release of Q3 FY26 performance data to the National Stock Exchange and BSE. Investors should now examine the detailed profit and loss statements to evaluate the company's operational efficiency and growth trajectory.
Key Highlights
Board approved unaudited standalone and consolidated financial results for the quarter ended December 31, 2025.
Approval granted for the financial results covering the nine-month period ending December 31, 2025.
Statutory Auditors issued a limited review report on the submitted financial statements.
The board meeting was conducted efficiently, lasting 30 minutes from 4:05 P.M. to 4:35 P.M. IST.
💼 Action for Investors
Investors should review the detailed financial tables once published to analyze revenue growth and margin trends. Compare these results against previous quarters to determine if the company is maintaining its growth momentum in the lifecare sector.
Jeena Sikho Lifecare Commences Operations at Two New Hospitals in Siliguri and Bhagalpur
Jeena Sikho Lifecare Limited (JSLL) has officially commenced operations at two new hospital facilities in Siliguri, West Bengal, and Bhagalpur, Bihar, effective February 3, 2026. The Siliguri facility adds 35 beds and 29 rooms, while the Bhagalpur unit adds 25 beds and 18 rooms to the company's healthcare network. Both facilities occupy 10,000 sq. ft. each and include dedicated OPD services. This expansion follows through on proposals initiated in 2025, demonstrating the company's commitment to scaling its physical infrastructure in the Eastern region.
Key Highlights
Commenced operations at two new hospitals in West Bengal and Bihar on February 3, 2026
Siliguri facility features 35 beds, 29 rooms, and 3 OPDs across 10,000 sq. ft.
Bhagalpur facility features 25 beds, 18 rooms, and 2 OPDs across 10,000 sq. ft.
Total capacity addition of 60 beds and 47 rooms across the two new locations
Execution of expansion plans within approximately one year of initial proposal
💼 Action for Investors
Investors should view this as a positive operational milestone that will likely contribute to revenue growth in the coming quarters. Monitor the occupancy rates and the company's ability to scale these new centers profitably.
JSLL to Engage with 25+ Institutional Investors at Nuvama 21st India Conference
Jeena Sikho Lifecare Limited (JSLL) has scheduled a series of group meetings with over 25 prominent institutional investors and asset management companies on February 10, 2026. The meetings will take place during the Nuvama 21st India Conference at Hotel Grand Hyatt, Mumbai. Participating entities include high-profile names such as PPFAS Mutual Fund, Motilal Oswal AMC, UTI Mutual Fund, and Aditya Birla Sun Life. These interactions are intended to discuss the company's business based on publicly available information, potentially increasing institutional visibility.
Key Highlights
Scheduled meetings with 25+ institutional investors and mutual funds on February 10, 2026.
Participation from top-tier funds including PPFAS Mutual Fund, Motilal Oswal AMC, and UTI Mutual Fund.
Four distinct group meeting slots scheduled between 10:00 AM and 1:50 PM.
Interaction organized as part of the Nuvama 21st India Conference in Mumbai.
💼 Action for Investors
Investors should monitor for any post-conference analyst reports or increased institutional buying activity. The high level of interest from reputed funds suggests growing institutional confidence in the company's business model.
JSLL Reports One-Year Disease-Free Cancer Care Success in Peer-Reviewed Ayush Journal
Jeena Sikho Lifecare Limited (JSLL) has published a clinical case report in the 'Ayush Journal of Integrative Oncology' documenting a successful outcome for a 53-year-old breast cancer survivor. The report highlights a one-year disease-free resolution of recurrent lymphadenopathy achieved through the company's proprietary Ayurvedic protocols and lifestyle modifications. Co-authored by the Managing Director and the R&D team, this publication provides evidence-based validation for JSLL's clinical practices. This move is intended to strengthen the company's credibility in the integrative oncology space and support its research-driven growth strategy.
Key Highlights
Published case report in 'Ayush Journal of Integrative Oncology' documents a one-year disease-free status for a post-mastectomy patient.
Clinical resolution was documented via PET-CT scans, providing objective evidence for the efficacy of the Ayurvedic interventions.
The publication was co-authored by Managing Director Acharya Manish Grover and JSLL's Department of Research and Development.
Treatment involved a combination of personalized Ayurvedic formulations, Panchakarma therapies, and a 'Circadian D.I.P. diet'.
The report reflects the company's commitment to advancing Ayurvedic research and evidence-based clinical practices.
💼 Action for Investors
Investors should view this as a positive step toward clinical validation of the company's treatments, which enhances brand trust and market positioning. Monitor for further R&D milestones that could drive long-term patient acquisition and revenue growth.
JSLL Approves AED 7.53 Million Unsecured Loan to International Subsidiary
Jeena Sikho Lifecare Limited (JSLL) has approved an unsecured loan of AED 7.53 million to its wholly-owned subsidiary, Jeena Sikho International LLC. The loan, to be disbursed in two tranches, carries an interest rate of 8.5% per annum with a tenure of five years to support the subsidiary's operational requirements. Separately, the company disclosed it has paid fines imposed by the NSE and BSE for past non-compliance with SEBI Regulation 29. This capital infusion suggests a focus on international expansion while the company works to strengthen its internal compliance systems.
Key Highlights
Approved an unsecured loan of AED 7.53 million to wholly-owned subsidiary Jeena Sikho International LLC
Loan features an interest rate of 8.5% per annum on a simple interest basis
The loan tenure is set for 5 years from the date of the first disbursement
Paid fines to NSE and BSE for non-compliance with Regulation 29 regarding board meeting intimations
Transaction is confirmed to be on an arm's length basis as a related party transaction
💼 Action for Investors
Investors should monitor the growth and revenue contribution of the international subsidiary following this capital infusion. Additionally, keep a watch on the company's future regulatory filings to ensure compliance issues are fully resolved.
Jeena Sikho Lifecare to Acquire 51% Stake in UAE-based Back to Roots Ayurveda for AED 1.53 Million
Jeena Sikho Lifecare Limited (JSLL) has announced that its international subsidiary will acquire a 51% controlling stake in Abu Dhabi-based Back to Roots Ayurveda for AED 1.53 million. This acquisition marks a significant step in JSLL's global expansion strategy within the Ayurveda and wellness sector. The target entity has shown rapid growth, with turnover increasing from AED 0.77 million in 2024 to AED 2.5 million in 2025. The transaction is expected to be completed within 2-3 months via cash consideration, making it a step-down subsidiary of JSLL.
Key Highlights
Acquisition of 51% equity stake in Back to Roots Ayurveda by Dr. Shyam LLC for AED 1.53 million.
Target company turnover grew over 220% year-on-year, reaching AED 2.5 million in 2025 from AED 0.77 million in 2024.
The deal establishes a strategic international footprint for JSLL in the UAE's growing wellness and Panchakarma market.
The acquisition is a cash-only transaction expected to be finalized within approximately 2-3 months.
Back to Roots Ayurveda is a relatively new entity, incorporated in December 2023, showing high growth potential.
💼 Action for Investors
Investors should look favorably on this international expansion as it diversifies revenue streams into a high-margin wellness market. Monitor the successful integration of the UAE operations and its impact on consolidated profitability in the next fiscal year.
Jeena Sikho Lifecare Partners with Theryco for Amazon E-commerce Distribution
Jeena Sikho Lifecare Limited (JSLL) has entered into a procurement agreement with Theryco Healthcare Solutions Private Limited to enhance its digital presence. Under this agreement, dated January 3, 2026, Theryco is authorized to list, manage, and sell JSLL's products on the Amazon e-commerce platform. This strategic move is intended to strengthen the company's distribution reach and improve product availability across digital channels. The company has confirmed that the transaction is on an arm's length basis and does not involve any related parties.
Key Highlights
Procurement agreement signed with Theryco Healthcare Solutions on January 3, 2026.
Theryco authorized to manage and sell JSLL products specifically on the Amazon platform.
Strategic focus on strengthening digital distribution and enhancing product availability.
Transaction confirmed as non-related party and executed on an arm's length basis.
💼 Action for Investors
Investors should monitor the company's upcoming quarterly results to see if this digital expansion translates into higher sales volumes. This move indicates a positive shift towards modernizing distribution channels.
JSLL Publishes Research on Ayurvedic Diabetes Care; HbA1c Drops from 7.3% to 6.4%
Jeena Sikho Lifecare Limited (JSLL) has published two research articles in international journals validating its Ayurvedic treatment protocols for Type 2 Diabetes and Chronic Kidney Disease. A key case study highlighted a patient's HbA1c reduction from 7.3% to 6.4% and a significant recovery in pancreatic function, with fecal elastase increasing from 102 µg/g to 694 µg/g. The study also reported a 50% reduction in triglycerides, from 439 mg/dl to 220 mg/dl, and a decrease in total cholesterol from 217 mg/dl to 157 mg/dl. These publications support the company's commitment to evidence-based Ayurveda and clinical advancement.
Key Highlights
Published two research papers in the European Journal of Pharmaceutical and Medical Research and IJAR
Patient HbA1c levels decreased from 7.3% to 6.4% following Ayurvedic intervention
Fecal pancreatic elastase levels improved significantly from 102 µg/g to 694 µg/g
Triglycerides were reduced by 50%, falling from 439 mg/dl to 220 mg/dl
Research authored by JSLL's Managing Director and senior medical consultants
💼 Action for Investors
This scientific validation enhances the company's clinical credibility and brand value in the competitive wellness sector. Long-term investors should monitor if such research leads to higher patient acquisition and revenue growth.
JSLL Sanganer Hospital Receives NABH Accreditation for Panchakarma Services
Jeena Sikho Lifecare Limited (JSLL) has successfully secured the National Accreditation Board for Hospitals & Healthcare Providers (NABH) certificate for its Sanganer Hospital in Rajasthan. The accreditation specifically covers Panchakarma services and is valid under certification number AH-2025-0412 until November 10, 2028. This certification validates the company's commitment to high standards of patient safety and quality healthcare delivery. Such accreditations are vital for healthcare providers to enhance brand reputation and facilitate empanelment with insurance providers.
Key Highlights
Received NABH Certificate of Accreditation for Sanganer Hospital located in Rajasthan.
The accreditation is specifically for Panchakarma services under certification number AH-2025-0412.
The certificate is valid for a multi-year period expiring on November 10, 2028.
Signifies adherence to nationally recognized standards for quality healthcare and operational excellence.
💼 Action for Investors
Investors should view this as a positive operational milestone that strengthens the company's competitive position in the Ayurvedic healthcare sector. Monitor for potential improvements in patient footfall and insurance tie-ups following this accreditation.
Jeena Sikho Lifecare Publishes Research on Ayurvedic CKD Treatment; Creatinine Levels Drop to 5.17
Jeena Sikho Lifecare Limited (JSLL) has announced the publication of three academic case studies and reports in international journals focusing on Ayurvedic management of Chronic Kidney Disease (CKD). A key case study highlighted in the filing demonstrated significant clinical improvements in a 56-year-old patient, with serum urea dropping from 230.86 mg/dL to 117.39 mg/dL and creatinine reducing from 6.32 mg/dL to 5.17 mg/dL. The research validates the company's proprietary Ayurvedic formulations and specialized 'DIP' diet protocols. These publications are part of JSLL's strategy to establish evidence-based credibility for its clinical practices and hospital-based treatments.
Key Highlights
Published three academic papers in the International Journal of Ayurveda and Herbal Research and Journal of Applied Science and Education.
Clinical results showed a significant serum urea reduction of approximately 49% (from 230.86 mg/dL to 117.39 mg/dL).
Serum creatinine levels improved from 6.32 mg/dL to 5.17 mg/dL during the observed treatment period.
Fasting blood sugar levels normalized from 130 mg/dL to 90 mg/dL, indicating improved metabolic control.
Research was co-authored by Managing Director Manish Grover and a team of senior Ayurvedic consultants and medical professionals.
💼 Action for Investors
Investors should view this as a positive step toward clinical validation of the company's Ayurvedic protocols, which could enhance brand trust and patient footfall. Monitor if this scientific validation leads to increased revenue in the hospital and wellness product segments.
JSLL Empanels 44 Ayurveda Hospitals with Medsave Health Insurance TPA for Cashless Treatment
Jeena Sikho Lifecare Limited (JSLL) has successfully empanelled 44 of its Ayurveda Panchkarma Hospitals with Medsave Health Insurance TPA Limited. This strategic arrangement enables the company to provide cashless Ayurvedic treatments to insured beneficiaries across a wide network of locations. The empanelment covers major Indian cities including Mumbai, Delhi, Bangalore, Hyderabad, and Kolkata, significantly enhancing service accessibility. This move is expected to drive higher patient footfall and revenue by integrating traditional treatments with mainstream insurance coverage.
Key Highlights
Empanelment of 44 Ayurveda Panchkarma Hospital locations across India with Medsave Health Insurance TPA.
Authorization to provide cashless treatment to insured beneficiaries under policies administered by Medsave.
Geographical footprint spans major hubs including Navi Mumbai, Bangalore, Ahmedabad, Pune, and Lucknow.
The arrangement is conducted in the ordinary course of business without any related party transactions.
💼 Action for Investors
Investors should monitor the impact of this empanelment on patient volumes and revenue growth in the upcoming quarters as insurance-backed Ayurvedic care gains traction. This development strengthens the company's competitive position in the organized wellness and healthcare sector.
JSLL Empanels 44 Ayurveda Hospitals with Medsave Health Insurance TPA for Cashless Treatment
Jeena Sikho Lifecare Limited (JSLL) has announced the empanelment of its Ayurveda Panchkarma Hospitals with Medsave Health Insurance TPA Limited. This strategic move covers 44 hospital locations across India, enabling the company to provide cashless treatment to insured beneficiaries. By integrating with a major TPA, JSLL is likely to see an increase in patient footfall as Ayurvedic treatments become more accessible through insurance. This development aligns with the company's efforts to formalize and scale its healthcare service offerings across multiple states.
Key Highlights
Empanelment of 44 Ayurveda Panchkarma Hospital locations with Medsave Health Insurance TPA.
Enables cashless treatment for beneficiaries covered under Medsave-administered health policies.
Network spans across key cities including Mumbai, Delhi, Bangalore, Hyderabad, and Chennai.
The arrangement is in the ordinary course of business and involves no related party transactions.
Expected to drive higher patient volumes by making specialized Ayurvedic care more affordable.
💼 Action for Investors
Investors should view this as a positive step toward increasing service accessibility and potential revenue growth. Monitor upcoming quarterly results for improvements in patient occupancy and average revenue per bed.
JSLL Empanels 44 Ayurveda Hospitals with Medsave TPA for Cashless Treatment
Jeena Sikho Lifecare Limited (JSLL) has announced the empanelment of 44 of its Ayurveda Panchkarma Hospitals with Medsave Health Insurance TPA Limited. This strategic move enables the company to provide cashless treatment to insured beneficiaries across a wide network of locations including major cities like Mumbai, Delhi, and Bangalore. By integrating with a TPA, JSLL is likely to see an increase in patient footfall from the insured segment, which has historically been a barrier for traditional Ayurvedic treatments. The empanelment is part of the company's ordinary course of business and aims to enhance service accessibility and revenue potential.
Key Highlights
Total of 44 hospital locations empanelled under the Medsave Health Insurance TPA network.
Enables cashless Ayurveda Panchkarma treatment for policyholders administered by Medsave TPA.
Network spans across multiple states including Maharashtra, Haryana, Uttar Pradesh, Rajasthan, and Karnataka.
The agreement is expected to drive higher utilization of hospital facilities and increase the addressable customer base.
💼 Action for Investors
Investors should view this as a positive step towards mainstreaming Ayurvedic treatments and expanding the company's market reach. Monitor the impact on quarterly patient volumes and revenue growth as these cashless facilities become operational.
JSLL Empanels 44 Ayurveda Hospitals with Medsave Health Insurance TPA for Cashless Treatment
Jeena Sikho Lifecare Limited (JSLL) has announced the empanelment of 44 of its Ayurveda Panchkarma Hospitals with Medsave Health Insurance TPA Limited. This strategic partnership enables the company to offer cashless treatment to insured beneficiaries across a vast network of locations including Mumbai, Bangalore, Delhi, and Chennai. By integrating with a major TPA, JSLL is positioned to increase patient footfall and revenue from the insured demographic. The arrangement is conducted in the ordinary course of business and involves no related party transactions.
Key Highlights
Empanelment of 44 hospital locations across India with Medsave Health Insurance TPA Limited.
Enables cashless Ayurveda Panchkarma treatments for insured beneficiaries.
Network covers major Tier-1 and Tier-2 cities including Mumbai, Bangalore, Hyderabad, and Kolkata.
Strategic move to increase patient volumes by making treatments more accessible through insurance coverage.
💼 Action for Investors
Investors should monitor the impact of this empanelment on the company's patient volume and revenue growth in upcoming quarters. This development strengthens JSLL's position in the organized wellness and Ayurvedic healthcare sector.
Jeena Sikho Lifecare Appoints Forvis Mazars LLP as Internal Auditor Following Resignation
Jeena Sikho Lifecare Limited (JSLL) has announced a change in its internal audit function effective December 23, 2025. The company accepted the resignation of M/s Deepak K Garg & Associates, who cited pre-occupation with other professional commitments as the reason for leaving. In their place, the Board has appointed M/s Forvis Mazars LLP, a leading international assurance and advisory firm, for the financial year 2025-26. This transition to a global firm is typically seen as a move to strengthen internal controls and corporate governance.
Key Highlights
Resignation of M/s Deepak K Garg & Associates as Internal Auditor effective December 23, 2025.
Appointment of M/s Forvis Mazars LLP as the new Internal Auditor for the FY 2025-26 period.
Outgoing auditor confirmed no material reasons for resignation other than professional commitments.
The Board meeting for approval was held on December 23, 2025, concluding within 15 minutes.
💼 Action for Investors
Investors should view the appointment of a globally recognized audit firm as a positive step for transparency and governance. No immediate portfolio action is required based on this routine management change.